SmithKline to act on pounds 90m pay packet
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.SMITHKLINE BEECHAM is expected to promise changes to its executive pay structure this week after widespread criticism from shareholders of the pounds 90m paid to chief executive Jan Leschly.
It is understood that Standard Life, the fund manager, which has a 2.1 per cent stake in the pharmaceuticals company, threatened to vote against SB's report and accounts at Tuesday's annual general meeting unless its concerns were addressed.
Guy Jubb, Standard Life's head of corporate governance, said: "Following useful discussions with the company, we understand that the chairman will signal change at the AGM which could lead to improvements in remuneration policy."
Standard Life is understood to have been concerned about SB's policy of basing executive pay on the performance of the company's share price and the level of its dividend, known as total shareholder return. SB shares have risen by more than 350 per cent since Mr Leschly became chief executive in 1994.
However, some fund managers are concerned that the system has rewarded Mr Leschly's performance when other drug company shares have risen almost as much. Shares in Glaxo and Zeneca, which has recently merged with Swedish group Astra, have also appreciated significantly but their chief executives earn considerably less than Mr Leschly.
In response to SB's concessions, Standard Life has taken into account the need for SB to compete with international pay practices by deciding only to abstain in Tuesday's vote.
SB has come in for widespread criticism for the generosity of Mr Leschly's package. The company's latest annual report revealed that he has earned pounds 90m in his nine years with the group. However, other UK shareholders - which include Mercury Asset Management, Legal & General and Prudential - do not share Standard Life's concern about Mr Leschly's earnings.
One UK fund manager said: "A lot of Mr Leschly's income has come from his SmithKline shares and we do encourage directors to own shares in their companies. SmithKline does have to recruit in an international market place."
A spokeswoman for SB played down the changes that chairman Sir Peter Walters will announce on Tuesday. "Each year our committee reviews the remuneration structure, which not only has to motivate but must also remain globally competitive."
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments